Reported 1 day ago
JP Morgan analyst Anupam Rama has assigned a neutral rating to ProKidney Corp. (NASDAQ:PROK) without a specific price target, citing the company's recent progress in obtaining an FDA accelerated approval pathway for rilparencel as a positive sign. Despite the optimistic developments in the pivotal PROACT 1 study, the timeline for the necessary data is longer than anticipated, with key results expected in Q2 2027, prompting a cautious outlook for investors.
Source: YAHOO